BriaCell Therapeutics Reports Increased Net Loss and Rising R&D Expenses in Latest Quarter

BriaCell Therapeutics Corp. reported a significant increase in its net loss for the three months ended October 31, 2025, amounting to $8.3 million, compared to a loss of $5.8 million during the same period in 2024. The company's operating expenses rose to $8.3 million, up from $5.2 million year-over-year, primarily driven by increased research and development costs associated with its pivotal Phase 3 clinical trial for Bria-IMT™ in metastatic breast cancer. Research and development expenses alone surged to $6.7 million, compared to $3.7 million in the prior year, reflecting heightened clinical trial activity and associated costs.

In terms of financial position, BriaCell's total assets decreased to $13.1 million as of October 31, 2025, down from $21.6 million at the end of July 2025. The decline in assets was accompanied by a reduction in cash and cash equivalents, which fell to $2.7 million from $10.5 million. The company reported a positive working capital of $8.0 million, down from $15.9 million, and an accumulated deficit of $120 million, indicating ongoing financial challenges as it continues to invest heavily in its clinical programs.

Strategically, BriaCell has made notable advancements in its clinical pipeline, including the ongoing Phase 3 study of Bria-IMT™, which is being conducted under FDA Fast Track designation. The company has expanded its clinical trial sites to 79 across 23 U.S. states, with plans to present positive biomarker data at the upcoming ESMO 2025 Congress. Additionally, BriaCell has received a $2 million Small Business Innovation Research grant from the U.S. National Cancer Institute to support its Bria-PROS+™ program in prostate cancer, further enhancing its funding sources.

Operationally, BriaCell's employee headcount has increased to support its expanding clinical operations, contributing to the rise in general and administrative expenses, which reached $1.6 million in the latest quarter. The company has also engaged in collaborations, including a partnership with Memorial Sloan Kettering Cancer Center to advance its Bria-OTS+™ platform, indicating a strategic focus on enhancing its research capabilities and market presence.

Looking ahead, BriaCell's management has expressed optimism about securing additional financing to support its ongoing operations and clinical trials. However, the company acknowledges the uncertainty surrounding its ability to raise sufficient capital, which is critical for its continued operations and achieving profitability. The outlook remains contingent on the successful advancement of its clinical programs and the ability to attract necessary funding in a challenging market environment.